PMID- 29997656
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1735-4587 (Print)
IS  - 2008-2215 (Electronic)
IS  - 1735-4587 (Linking)
VI  - 13
IP  - 2
DP  - 2018 Apr
TI  - Attention-Deficit Hyperactivity Disorder in Adults Using Methamphetamine: Does It 
      Affect Comorbidity, Quality of Life, and Global Functioning?
PG  - 111-118
AB  - Objective: Attention-deficit hyperactivity disorder (ADHD) is common in 
      adulthood, and it is associated with different high- risk behaviors, particularly 
      substance use. Evidence suggests a high prevalence of ADHD in adults who take 
      methamphetamine (METH). This study aimed at comparing functional level, quality 
      of life, and psychiatric comorbidities in METH users with and without adult ADHD 
      (A-ADHD). Method: In this cross-sectional study, 134 patients who had a history 
      of METH use (at least once in lifetime) were selected from among inpatient and 
      outpatient referrals to a psychiatric hospital. DIVA was performed for those who 
      were positive on the Conners' Adult ADHD Rating Scales-Self-Report-Screening 
      Version (CAARS-SR-SV). The Global Assessment of Functioning (GAF) and World 
      Health Organization Quality of Life Scale-Brief (WHOQoL-BREF) were used to assess 
      the participants' level of functioning and quality of life, respectively. 
      Psychiatric comorbidities including substance use disorders were evaluated using 
      the Structured Clinical Interview for DSM-IV-Axis I (SCID-I). Results: Among the 
      METH users, 10.4% were diagnosed as having A-ADHD. A-ADHD was more prevalent 
      among female METH users than males. The hyperactive-impulsive and combined types 
      were more common than the inattentive type. Opiates and cannabis were the most 
      commonly abused drugs by the 2 groups, while sedative-hypnotic use was 
      significantly higher in the individuals with A-ADHD. Substance-induced mood 
      disorder was the most prevalent comorbidity in the 2 groups and was higher in 
      those with A-ADHD. quality of life and the GAF scores were significantly lower in 
      those with A-ADHD and duration of METH use was higher Compared to the METH users 
      without A-ADHD, (p>0.05). Conclusion: This study provided some preliminary 
      findings supporting the prevalence of Adult ADHD among METH users and its 
      negative impacts on their global functioning and quality of life. To provide more 
      effective intervention for METH users, detection and treatment of those with 
      A-ADHD can be of clinical value.
FAU - Mihan, Ronak
AU  - Mihan R
AD  - Psychiatry Faculty, University of Social Welfare and Rehabilitation Sciences, 
      Tehran, Iran.
FAU - Shahrivar, Zahra
AU  - Shahrivar Z
AD  - Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran.
AD  - Research Center for Cognitive and Behavioral Sciences, Tehran University of 
      Medical Sciences, Tehran, Iran.
FAU - Mahmoudi-Gharaei, Javad
AU  - Mahmoudi-Gharaei J
AD  - Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Shakiba, Alia
AU  - Shakiba A
AD  - Psychiatry and Psychology Research Center, Tehran University of Medical Sciences, 
      Tehran, Iran.
FAU - Hosseini, Mostafa
AU  - Hosseini M
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Tehran 
      University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Iran J Psychiatry
JT  - Iranian journal of psychiatry
JID - 101302041
PMC - PMC6037581
OTO - NOTNLM
OT  - Adult
OT  - Attention Deficit Hyperactivity Disorder
OT  - Comorbidity
OT  - Function
OT  - Methamphetamine
OT  - Quality of Life
EDAT- 2018/07/13 06:00
MHDA- 2018/07/13 06:01
PMCR- 2018/04/01
CRDT- 2018/07/13 06:00
PHST- 2018/07/13 06:00 [entrez]
PHST- 2018/07/13 06:00 [pubmed]
PHST- 2018/07/13 06:01 [medline]
PHST- 2018/04/01 00:00 [pmc-release]
AID - IJPS-13-112 [pii]
PST - ppublish
SO  - Iran J Psychiatry. 2018 Apr;13(2):111-118.